{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:47:50Z","timestamp":1772498870058,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Taishan Scholars Program of Shandong Province","award":["No. tsqn202306403"],"award-info":[{"award-number":["No. tsqn202306403"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The therapeutic role of extracorporeal shockwave therapy (ESWT) for Peyronie\u2019s disease (PD) has been controversial in a long term. We aimed to further evaluate the therapeutic effect of ESWT for PD on the basis of available high-quality studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The PubMed, CENTRAL and Embase databases were searched for articles published from January 1st, 2000 to December 31, 2022. Only randomized controlled trials (RCTs) using ESWT to treat PD were included. Meta-analysis and forest plots were carried out using Review Manager 5.4.1 software, and outcomes were reviewed by 2 authors independently. Using the Risk of Bias assessment form (ROB-2) by Cochrane Collaboration for quality assessment. PRISMA 2020 guidelines were used in this article to achieve the quantitative and qualitative synthesis of data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of four RCTs were included. 151 patients in the ESWT group and 150 patients in the control group. The meta-analysis results showed that ESWT could significantly reduce plaque size (OR 2.59, 95%CI 1.15 to 5.85, P\u2009=\u20090.02) and relieve pain (MD -1.55, 95%CI -2.46 to -0.64, P\u2009=\u20090.0008); but it has no significant effect on reducing the penile curvature (OR 1.93, 95%CI 0.87\u20134.26, P\u2009=\u20090.11) and improving sexual function (MD 2.6, 95%CI -1.63 to 6.83, P\u2009=\u20090.23), there is also no significant difference in complication rates between groups (OR 2.94, 95%CI 0.66 to 13.03, P\u2009=\u20090.16). The risk of bias of results is low. The limitations of this study are that the number of included studies is too small, some experimental outcomes are missing, and the expression of outcomes is not unified.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>For PD, ESWT can be considered as a safe short-term treatment, which can reduce plaque size and relieve pain, but cannot improve penile curvature and sexual function. Its long-term efficacy remains to be discussed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Registration number<\/jats:title>\n                <jats:p>PROSPERO (ID: CRD42023436744).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12894-023-01320-8","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T18:02:04Z","timestamp":1694541724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Updated recommendations on the therapeutic role of extracorporeal shock wave therapy for peyronie\u2019s disease: systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiaofeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongquan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonglin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongli","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanshan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"1320_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.21037\/tau.2016.11.01","volume":"6","author":"J Campbell","year":"2017","unstructured":"Campbell J, Alzubaidi R. Understanding the cellular basis and pathophysiology of Peyronie\u2019s disease to optimize treatment for erectile dysfunction. Transl Androl Urol. 2017;6:46\u201359. https:\/\/doi.org\/10.21037\/tau.2016.11.01.","journal-title":"Transl Androl Urol"},{"key":"1320_CR2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jsxm.2016.04.062","volume":"13","author":"E Chung","year":"2016","unstructured":"Chung E, Ralph D, Kagioglu A, Garaffa G, Shamsodini A, Bivalacqua T, Glina S, Hakim L, Sadeghi-Nejad H, Broderick G. Evidence-based management guidelines on Peyronie\u2019s Disease. J Sex Med. 2016;13:905\u201323. https:\/\/doi.org\/10.1016\/j.jsxm.2016.04.062.","journal-title":"J Sex Med"},{"key":"1320_CR3","doi-asserted-by":"publisher","first-page":"e0150157","DOI":"10.1371\/journal.pone.0150157","volume":"11","author":"M Stuntz","year":"2016","unstructured":"Stuntz M, Perlaky A, des Vignes F, Kyriakides T, Glass D. The prevalence of Peyronie\u2019s Disease in the United States: a Population-Based study. PLoS ONE. 2016;11:e0150157. https:\/\/doi.org\/10.1371\/journal.pone.0150157.","journal-title":"PLoS ONE"},{"key":"1320_CR4","doi-asserted-by":"publisher","first-page":"282503","DOI":"10.1155\/2011\/282503","volume":"2011","author":"DB Dibenedetti","year":"2011","unstructured":"Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A Population-Based study of Peyronie\u2019s Disease: prevalence and treatment patterns in the United States. Adv Urol. 2011;2011:282503. https:\/\/doi.org\/10.1155\/2011\/282503.","journal-title":"Adv Urol"},{"key":"1320_CR5","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1111\/j.1743-6109.2010.01850.x","volume":"7","author":"D Ralph","year":"2010","unstructured":"Ralph D, Gonzalez-Cadavid N, Mirone V, Perovic S, Sohn M, Usta M, Levine L. The management of Peyronie\u2019s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7:2359\u201374. https:\/\/doi.org\/10.1111\/j.1743-6109.2010.01850.x.","journal-title":"J Sex Med"},{"key":"1320_CR6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.21037\/tau.2016.04.05","volume":"5","author":"S Al-Thakafi","year":"2016","unstructured":"Al-Thakafi S, Al-Hathal N. Peyronie\u2019s disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up. Transl Androl Urol. 2016;5:280\u20139. https:\/\/doi.org\/10.21037\/tau.2016.04.05.","journal-title":"Transl Androl Urol"},{"key":"1320_CR7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41443-021-00430-x","volume":"34","author":"OI Moghalu","year":"2022","unstructured":"Moghalu OI, Das R, Horns J, Campbell A, Hotaling JM, Pastuszak AW. Trends in treatment of Peyronie\u2019s disease in adult men in the United States from 2008 to 2017-results from an encounter and claims database. Int J Impot Res. 2022;34:280\u20138. https:\/\/doi.org\/10.1038\/s41443-021-00430-x.","journal-title":"Int J Impot Res"},{"key":"1320_CR8","first-page":"417","volume":"61","author":"C Bellorofonte","year":"1989","unstructured":"Bellorofonte C, Ruoppolo M, Tura M, Zaatar C, Tombolini P, Menchini GF, Fabris. [Possibility of using the piezoelectric lithotriptor in the treatment of severe cavernous fibrosis]. Arch Ital Urol Nefrol Androl. 1989;61:417\u201322.","journal-title":"Arch Ital Urol Nefrol Androl"},{"key":"1320_CR9","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1524-475X.2012.00796.x","volume":"20","author":"R Mittermayr","year":"2012","unstructured":"Mittermayr R, Antonic V, Hartinger J, Kaufmann H, Redl H, Teot L, Stojadinovic A, Schaden W. Extracorporeal shock wave therapy (ESWT) for wound healing: technology, mechanisms, and clinical efficacy. Wound Repair Regen. 2012;20:456\u201365. https:\/\/doi.org\/10.1111\/j.1524-475X.2012.00796.x.","journal-title":"Wound Repair Regen"},{"key":"1320_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2012.05.040","volume":"62","author":"K Hatzimouratidis","year":"2012","unstructured":"Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A, Vardi Y, Wespes E, European Association of. EAU guidelines on penile curvature. Eur Urol. 2012;62:543\u201352. https:\/\/doi.org\/10.1016\/j.eururo.2012.05.040.","journal-title":"Eur Urol"},{"key":"1320_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/01.ju.0000099891.68488.4e","volume":"171","author":"EW Hauck","year":"2004","unstructured":"Hauck EW, Hauptmann A, Bschleipfer T, Schmelz HU, Altinkilic BM, Weidner W. Questionable efficacy of extracorporeal shock wave therapy for Peyronie\u2019s disease: results of a prospective approach. J Urol. 2004;171:296\u20139. https:\/\/doi.org\/10.1097\/01.ju.0000099891.68488.4e.","journal-title":"J Urol"},{"key":"1320_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/089277903321196788","volume":"17","author":"MS Michel","year":"2003","unstructured":"Michel MS, Ptaschnyk T, Musial A, Braun P, Lenz ST, Alken P, K\u00f6hrmann KU. Objective and subjective changes in patients with Peyronie\u2019s disease after management with shockwave therapy. J Endourol. 2003;17:41\u20134. https:\/\/doi.org\/10.1089\/089277903321196788. discussion 44.","journal-title":"J Endourol"},{"key":"1320_CR13","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/sj.ijir.3901192","volume":"16","author":"RT Strebel","year":"2004","unstructured":"Strebel RT, Suter S, Sautter T, Hauri D. Extracorporeal shockwave therapy for Peyronie\u2019s disease does not correct penile deformity. Int J Impot Res. 2004;16:448\u201351. https:\/\/doi.org\/10.1038\/sj.ijir.3901192.","journal-title":"Int J Impot Res"},{"key":"1320_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/01.ju.0000108060.30363.8d","volume":"171","author":"EW Hauck","year":"2004","unstructured":"Hauck EW, Mueller UO, Bschleipfer T, Schmelz HU, Diemer T, Weidner W. Extracorporeal shock wave therapy for Peyronie\u2019s disease: exploratory meta-analysis of clinical trials. J Urol. 2004;171:740\u20135. https:\/\/doi.org\/10.1097\/01.ju.0000108060.30363.8d.","journal-title":"J Urol"},{"key":"1320_CR15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1159\/000020359","volume":"38","author":"EW Hauck","year":"2000","unstructured":"Hauck EW, Altinkilic BM, Ludwig M, L\u00fcdecke G, Schroeder-Printzen I, Arens C, Weidner W. Extracorporal shock wave therapy in the treatment of Peyronie\u2019s disease. First results of a case-controlled approach. Eur Urol. 2000;38:663\u20139. https:\/\/doi.org\/10.1159\/000020359. Discussion 670.","journal-title":"Eur Urol"},{"key":"1320_CR16","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/s0022-5347(17)39746-x","volume":"144","author":"MK Gelbard","year":"1990","unstructured":"Gelbard MK, Dorey F, James K. The natural history of Peyronie\u2019s disease. J Urol. 1990;144:1376\u20139. https:\/\/doi.org\/10.1016\/s0022-5347(17)39746-x.","journal-title":"J Urol"},{"key":"1320_CR17","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.eururo.2007.07.013","volume":"53","author":"A Bekos","year":"2008","unstructured":"Bekos A, Arvaniti M, Hatzimouratidis K, Moysidis K, Tzortzis V, Hatzichristou D. The natural history of Peyronie\u2019s disease: an ultrasonography-based study. Eur Urol. 2008;53:644\u201350. https:\/\/doi.org\/10.1016\/j.eururo.2007.07.013.","journal-title":"Eur Urol"},{"key":"1320_CR18","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1046\/j.1464-410x.2000.00827.x","volume":"86","author":"J Husain","year":"2000","unstructured":"Husain J, Lynn NN, Jones DK, Collins GN, O\u2019Reilly PH. Extracorporeal shock wave therapy in the management of Peyronie\u2019s disease: initial experience. BJU Int. 2000;86:466\u20138. https:\/\/doi.org\/10.1046\/j.1464-410x.2000.00827.x.","journal-title":"BJU Int"},{"key":"1320_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ijir.2016.24","volume":"28","author":"L Gao","year":"2016","unstructured":"Gao L, Qian S, Tang Z, Li J, Yuan J. A meta-analysis of extracorporeal shock wave therapy for Peyronie\u2019s disease. Int J Impot Res. 2016;28:161\u20136. https:\/\/doi.org\/10.1038\/ijir.2016.24.","journal-title":"Int J Impot Res"},{"key":"1320_CR20","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.jsxm.2021.06.012","volume":"18","author":"AM Bakr","year":"2021","unstructured":"Bakr AM, El-Sakka AI. Extracorporeal shockwave therapy in Peyronie\u2019s Disease: systematic review and Meta-analysis. J Sex Med. 2021;18:1705\u201314. https:\/\/doi.org\/10.1016\/j.jsxm.2021.06.012.","journal-title":"J Sex Med"},{"key":"1320_CR21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.eururo.2009.05.012","volume":"56","author":"A Palmieri","year":"2009","unstructured":"Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, Creta M, Mirone V. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie\u2019s disease. Eur Urol. 2009;56:363\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2009.05.012.","journal-title":"Eur Urol"},{"key":"1320_CR22","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/j.1464-410X.2010.09331.x","volume":"106","author":"S Chitale","year":"2010","unstructured":"Chitale S, Morsey M, Swift L, Sethia K. Limited shock wave therapy vs sham treatment in men with Peyronie\u2019s disease: results of a prospective randomized controlled double-blind trial. BJU Int. 2010;106:1352\u20136. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09331.x.","journal-title":"BJU Int"},{"key":"1320_CR23","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1111\/jsm.12275","volume":"10","author":"G Hatzichristodoulou","year":"2013","unstructured":"Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in Peyronie\u2019s disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med. 2013;10:2815\u201321. https:\/\/doi.org\/10.1111\/jsm.12275.","journal-title":"J Sex Med"},{"key":"1320_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41443-021-00447-2","volume":"34","author":"I Sokolakis","year":"2022","unstructured":"Sokolakis I, Pyrgidis N, Lahme S, Hatzichristodoulou G. Low-intensity shockwave therapy in Peyronie\u2019s disease: long-term results from a prospective, randomized, sham-controlled trial. Int J Impot Res. 2022;34:487\u201394. https:\/\/doi.org\/10.1038\/s41443-021-00447-2.","journal-title":"Int J Impot Res"},{"key":"1320_CR25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1046\/j.1442-2042.2002.00430.x","volume":"9","author":"H Kiyota","year":"2002","unstructured":"Kiyota H, Ohishi Y, Asano K, Hasegawa N, Madarame J, Miki K, Kato N, Kimura T, Ishiyama T, Maeda S, Shimomura T, Shiono Y, Miki J. Extracorporeal shock wave treatment for Peyronie\u2019s disease using EDAP LT-02; preliminary results. Int J Urol. 2002;9:110\u20133. https:\/\/doi.org\/10.1046\/j.1442-2042.2002.00430.x.","journal-title":"Int J Urol"},{"key":"1320_CR26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/s0090-4295(02)01970-2","volume":"60","author":"R Manikandan","year":"2002","unstructured":"Manikandan R, Islam W, Srinivasan V, Evans CM. Evaluation of extracorporeal shock wave therapy in Peyronie\u2019s disease. Urology. 2002;60:795\u20139. https:\/\/doi.org\/10.1016\/s0090-4295(02)01970-2. discussion 799\u2013800.","journal-title":"Urology"},{"key":"1320_CR27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2147\/rru.S325929","volume":"13","author":"J Mortensen","year":"2021","unstructured":"Mortensen J, Skov-Jeppesen SM, Ladegaard PBJ, Lund L. A Randomized, single-blinded clinical trial evaluating the effect of extracorporeal Shockwave treatment (ESWT) as Add-On therapy to Vacuum Erectile device on Peyronie\u2019s Disease. Res Rep Urol. 2021;13:715\u201322. https:\/\/doi.org\/10.2147\/rru.S325929.","journal-title":"Res Rep Urol"},{"key":"1320_CR28","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","volume":"175","author":"JP Mulhall","year":"2006","unstructured":"Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie\u2019s disease. J Urol. 2006;175:2115\u20138. https:\/\/doi.org\/10.1016\/S0022-5347(06)00270-9. discussion 2118.","journal-title":"J Urol"},{"key":"1320_CR29","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.eururo.2007.06.032","volume":"53","author":"A Muller","year":"2008","unstructured":"Muller A, Akin-Olugbade Y, Deveci S, Donohue JF, Tal R, Kobylarz KA, Palese M, Mulhall JP. The impact of shock wave therapy at varied energy and dose levels on functional and structural changes in erectile tissue. Eur Urol. 2008;53:635\u201342. https:\/\/doi.org\/10.1016\/j.eururo.2007.06.032.","journal-title":"Eur Urol"},{"key":"1320_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/rru.S141748","volume":"9","author":"G Paulis","year":"2017","unstructured":"Paulis G, Paulis A, Romano G, Barletta D, Fabiani A. Rationale of combination therapy with antioxidants in medical management of Peyronie\u2019s disease: results of clinical application. Res Rep Urol. 2017;9:129\u201339. https:\/\/doi.org\/10.2147\/rru.S141748.","journal-title":"Res Rep Urol"},{"key":"1320_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s13256-022-03614-1","volume":"16","author":"G Paulis","year":"2022","unstructured":"Paulis G, De Giorgio G. Patients with Peyronie\u2019s disease achieve complete plaque regression after multimodal treatment with antioxidants: a case series. J Med Case Rep. 2022;16:359. https:\/\/doi.org\/10.1186\/s13256-022-03614-1.","journal-title":"J Med Case Rep"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-023-01320-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-023-01320-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-023-01320-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T21:13:31Z","timestamp":1700514811000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-023-01320-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1320"],"URL":"https:\/\/doi.org\/10.1186\/s12894-023-01320-8","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]},"assertion":[{"value":"20 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"145"}}